| Identification | Back Directory | [Name]
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[4-[(4-ethyl-1-piperazinyl)methyl]-2-fluoro-5-(trifluoromethyl)phenyl]- | [CAS]
2684258-54-4 | [Synonyms]
RET-IN-13
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[4-[(4-ethyl-1-piperazinyl)methyl]-2-fluoro-5-(trifluoromethyl)phenyl]- | [Molecular Formula]
C32H33F4N5O3 | [MOL File]
2684258-54-4.mol | [Molecular Weight]
611.63 |
| Hazard Information | Back Directory | [Uses]
RET-IN-13 (compound 1), a quinoline compound, is a potent RET inhibitor with IC50s of 0.5 nM, 0.9 nM for RET (WT) and RET (V804M), respectively. RET-IN-13 has the potential for tumors or intestinal diseases related to abnormal activation of RET research[1]. | [in vivo]
RET-IN-13 (compound 1; 0.5 mpk; iv) has a T1/2 of 6.93 hours, a CL of 2.68 mL/min·kg, and a Vdss of 1.52 L/kg for male mice[1].
RET-IN-13 (2.5 mpk; po) has a T1/2 of 5.16 hours, Cmax of 0.958 μM and an AUC of 12477 μM·hr for male mice[1].
| [References]
[1] Jiansong Wang, et al. Quinoline compounds. WO2021164742A1. |
|
|